Nxera Pharma , Ltd. Receivables

Nxera Pharma , Ltd. (SOLTF) currently reports a receivables of $11B as of June 2026. That compares with $6.8B in the prior-year period — up 56.0% year over year. Use the charts on this page to explore Nxera Pharma , Ltd.'s receivables history and peer comparisons.

Nxera Pharma , Ltd.'s receivables increased from $6.8B to $11B — a 56.0% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Nxera Pharma , Ltd. reported $11B in receivables as of June 2026. That compares with $6.8B in the prior-year period — up 56.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $11B, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Nxera Pharma , Ltd., and consider following SOLTF for alerts when major investors trade the stock.

Nxera Pharma , Ltd. is classified in the Healthcare sector. On receivables, it currently shows $11B. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing SOLTF with unrelated industries.